HER2 Diagnostic Concordance Among Pathologists Increases Significantly When Using Qanti Breast HER2 AIVIS (CEO Daehong Lee), a leader in AI-driven pathology analysis solutions, announced on the 16th that it successfully presented research validating its AI-powered HER2 diagnostic technology at the 2025 Breast Cancer Dx Symposium, hosted by AstraZeneca Korea on November 21. Held at the JW Marriott Hotel Seoul, the symposium brought together leading breast pathology experts to discuss accurate HER2 assessment—an area of growing importance with the rise of advanced treatments such as Enhertu (trastuzumab deruxtecan), which is reshaping the therapeutic landscape in breast cancer. Many members of the Korean Society of Pathologists’ Breast Pathology Study Group attended, underscoring the increasing need for precision diagnostics in clinical decision-making. During the session titled “2025 Study Summary of the Korean Breast Pathology Study Group,” Professor Eun Yoon Cho of Samsung Medical Center presented results from an evaluation study using AIVIS’s Qanti Breast HER2 solution. The findings demonstrated a marked improvement in both diagnostic accuracy and concordance among pathologists—particularly in HER2 ultralow cases, which are notoriously difficult to interpret through visual assessment alone. Recognized for its scientific and clinical significance, the study has been accepted as an abstract at ESMO Asia 2025 (European Society for Medical Oncology Asia Congress), which will be held in Singapore this December. AIVIS plans to present detailed data and discuss the broader implications for global precision oncology during the conference. Following this, Professor Ahwon Lee of Seoul St. Mary’s Hospital delivered a presentation titled “New Standards in Precision Care,” offering insights into evolving policies in HER2 companion diagnostics and the emerging need for more sophisticated diagnostic tools. He emphasized that AI technologies like AIVIS’s platform could play a pivotal role in supporting efficient and accurate pathological decision-making amid the growing adoption of antibody–drug conjugate (ADC) therapies. AIVIS’s Chief Medical Officer, Dr. Gyuyeong Kim, also took the stage with a talk titled “From Algorithm to Action: Real-World Experiences with AI in HER2-Ultralow Diagnosis.” He demonstrated how Qanti is applied in daily pathology workflows, detailing the technical principles behind its cancer-cell detection and HER2 expression quantification capabilities. Dr. Kim also engaged in active discussion with clinicians, transparently sharing both strong performance outcomes and areas targeted for future algorithm refinement. “This symposium was an important opportunity to show healthcare professionals how AIVIS technology can meaningfully improve diagnostic accuracy in real-world practice,” said AIVIS CEO Daehong Lee. “We will continue strengthening global awareness of Qanti’s capabilities through major domestic and international conferences, contributing to the advancement of precision medicine.”